Can one device do the job of two? TAVR study tests simpler artery closure
NCT ID NCT06871774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using just one Perclose device to close the artery after TAVR is as safe and effective as the usual two devices. Researchers will measure bleeding time and complications in 300 adults undergoing TAVR. The goal is to see if a simpler approach can reduce procedure time and risks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Perclose vascular closure device
- What this could lead to
- If one device works as well as two, it could simplify the TAVR procedure, reduce costs, and shorten recovery time.
- What could go wrong
- This is a small, early-stage trial focused on procedural technique, not a new treatment. Using one device might increase the risk of bleeding or complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient age 18 or older * Transfemoral transcatheter aortic valve replacement (TAVR) * Implantation of CoreValve replacement valve * Access using 14 French sheaths * English speaking Exclusion Criteria: * Alternative Access Routes: Patients undergoing transcatheter aortic valve replacement (TAVR) via alternative access routes such as subclavian access or transapical access. * Planned Surgical Cut-Down: Patients planned for surgical cut-down procedures rather than percutaneous access. * Vascular Access Complications: Patients with known vascular complications at the femoral access site, such as residual hematoma, recent femoral arteriotomy or venotomy within the past 10 days, history of significant vascular complications or prior intravascular closure device use within the previous 30 days. * Arterial or Venous Issues: Patients with small femoral arteries or veins (\<5 mm in diameter), patients with access sites located in vascular grafts. * Body Composition: Patients with BMI \>35 * Cardiac Vasculature: Patients with excess calcification of vessels as determined by echocardiography and/or CT angiography * Infection or Inflammation: Active systemic or cutaneous infection or inflammation in the vicinity of the groin. * Coagulation and Hematological Disorders: Known history of bleeding diathesis, coagulopathy, hypercoagulability, or platelet count \<100,000 cells/mm³. Pre-existing immunodeficiency disorder or chronic use of high-dose systemic steroids. * Severe Morbidity: Severe co-existing morbidities with a life expectancy less than 12 months. * Mobility Issues: Patients unable to routinely walk at least 20 feet without assistance. * Recent Anticoagulation: Use of low molecular weight heparin (LMWH) within 8 hours before or after the procedure. * Pregnancy and Lactation: Pregnant or lactating women. * Incompatible Procedure Plan: Patients receiving the Edwards Sapien valve (Edwards Lifesciences, Irvine, CA) * Contraindications: Patients with contraindications for the use of Perclose device.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aurora St. Luke's Medical Center
RECRUITINGMilwaukee, Wisconsin, 53215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI turns routine heart tracings into an early warning for a silent valve disease
- Can a new heart valve offer a safer fix for aortic stenosis?
- Can Open-Heart surgery outperform a Tube-Based valve fix?
- Can a new heart valve restore quality of life?
- Does replacing a heart valve clear fluid from the lungs?
- AI ultrasound could unmask silent heart disease in seniors